These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Role of cd56 and e-cadherin expression in the differential diagnosis of papillary thyroid carcinoma and suspected follicular-patterned lesions of the thyroid: the prognostic importance of e-cadherin. Ceyran AB; Şenol S; Şimşek BÇ; Sağıroğlu J; Aydın A Int J Clin Exp Pathol; 2015; 8(4):3670-80. PubMed ID: 26097548 [TBL] [Abstract][Full Text] [Related]
4. The Role of CD56 in Thyroid Fine Needle Aspiration Cytology: A Pilot Study Performed on Liquid Based Cytology. Bizzarro T; Martini M; Marrocco C; D'Amato D; Traini E; Lombardi CP; Pontecorvi A; Fadda G; Larocca LM; Rossi ED PLoS One; 2015; 10(7):e0132939. PubMed ID: 26186733 [TBL] [Abstract][Full Text] [Related]
5. Immunohistochemical expression of HBME-1 and galectin-3 in the differential diagnosis of follicular-derived thyroid nodules. Abd-El Raouf SM; Ibrahim TR Pathol Res Pract; 2014 Dec; 210(12):971-8. PubMed ID: 25041837 [TBL] [Abstract][Full Text] [Related]
6. Diagnostic value of HBME-1, CD56, Galectin-3 and Cytokeratin-19 in papillary thyroid carcinomas and thyroid tumors of uncertain malignant potential. Nechifor-Boilă A; Cătană R; Loghin A; Radu TG; Borda A Rom J Morphol Embryol; 2014; 55(1):49-56. PubMed ID: 24715165 [TBL] [Abstract][Full Text] [Related]
7. Differential diagnostic significance of HBME-1, CK19 and S100 in various thyroid lesions. Palo S; Biligi DS Malays J Pathol; 2017 Apr; 39(1):55-67. PubMed ID: 28413206 [TBL] [Abstract][Full Text] [Related]
8. Immunohistochemical study of papillary thyroid carcinoma and possible papillary thyroid carcinoma-related benign thyroid nodules. Mai KT; Ford JC; Yazdi HM; Perkins DG; Commons AS Pathol Res Pract; 2000; 196(8):533-40. PubMed ID: 10982016 [TBL] [Abstract][Full Text] [Related]
9. Expression of HBME-1 and CD56 in follicular variant of papillary carcinoma in children: An immunohistochemical study and their diagnostic utility. Skaria PE; Ahmed AA; Yin H; Nicol K; Reid KJ; Singh V Pathol Res Pract; 2019 May; 215(5):880-884. PubMed ID: 30711197 [TBL] [Abstract][Full Text] [Related]
10. [Expression of cytokeratin19, galectin-3 and HBME-1 in thyroid lesions and their differential diagnoses]. Teng XD; Wang LJ; Yao HT; Li J; Ding W; Yan LP Zhonghua Bing Li Xue Za Zhi; 2004 Jun; 33(3):212-6. PubMed ID: 15256110 [TBL] [Abstract][Full Text] [Related]
11. Potential diagnostic utility of CD56 and claudin-1 in papillary thyroid carcinoma and solitary follicular thyroid nodules. Abd El Atti RM; Shash LS J Egypt Natl Canc Inst; 2012 Dec; 24(4):175-84. PubMed ID: 23159288 [TBL] [Abstract][Full Text] [Related]
13. Improvement of the cytological diagnostic accuracy of follicular thyroid lesions by the use of the Ki-67 proliferative index in addition to cytokeratin-19 and HBME-1 immunomarkers: a study of 61 cases of liquid-based FNA cytology with histological controls. Lacoste-Collin L; d'Aure D; Bérard E; Rouquette I; Delisle MB; Courtade-Saïdi M Cytopathology; 2014 Jun; 25(3):160-9. PubMed ID: 24460983 [TBL] [Abstract][Full Text] [Related]
14. CD56, HBME-1 and cytokeratin 19 expressions in papillary thyroid carcinoma and nodular thyroid lesions. Erdogan-Durmus S; Ozcan D; Yarikkaya E; Kurt A; Arslan A J Res Med Sci; 2016; 21():49. PubMed ID: 27904595 [TBL] [Abstract][Full Text] [Related]
15. Atypical thyroid nodules express both HBME-1 and Galectin-3, two phenotypic markers of papillary thyroid carcinoma. Coli A; Bigotti G; Parente P; Federico F; Castri F; Massi G J Exp Clin Cancer Res; 2007 Jun; 26(2):221-7. PubMed ID: 17725102 [TBL] [Abstract][Full Text] [Related]
16. CD56 expression in benign and malignant thyroid lesions. Muthusamy S; Azhar Sha S; Abdullah Suhaimi SN; Kassim N; Mahasin M; Mohd Saleh MF; Md Isa N Malays J Pathol; 2018 Aug; 40(2):111-119. PubMed ID: 30173227 [TBL] [Abstract][Full Text] [Related]
17. Diagnostic value of CD56 immunohistochemistry in thyroid lesions. Pyo JS; Kim DH; Yang J Int J Biol Markers; 2018 May; 33(2):161-167. PubMed ID: 29799356 [TBL] [Abstract][Full Text] [Related]
18. Thyroid tumors of uncertain malignant potential: morphologic and imunohistochemical analysis of 29 cases. Nechifor-Boila A; Borda A; Sassolas G; Hafdi-Nejjari Z; Cătană R; Borson-Chazot F; Berger N; Decaussin-Petrucci M Pathol Res Pract; 2015 Apr; 211(4):320-5. PubMed ID: 25595997 [TBL] [Abstract][Full Text] [Related]
19. Diagnostic utility of CK19 and CD56 in the differentiation of thyroid papillary carcinoma from its mimics. Abouhashem NS; Talaat SM Pathol Res Pract; 2017 May; 213(5):509-517. PubMed ID: 28214214 [TBL] [Abstract][Full Text] [Related]
20. The diagnostic value of TROP-2, SLP-2 and CD56 expression in papillary thyroid carcinoma. Yang X; Hu Y; Shi H; Zhang C; Wang Z; Liu X; Chen H; Zhang L; Cui D Eur Arch Otorhinolaryngol; 2018 Aug; 275(8):2127-2134. PubMed ID: 29951933 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]